Day One Biopharmaceuticals in pact with MabCare  for MTX-13 targeting PTK7
PremiumThe FlyDay One Biopharmaceuticals in pact with MabCare for MTX-13 targeting PTK7
1M ago
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
PremiumPress Releases
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
1M ago
Day One Biopharmaceuticals Updates FIREFLY-2 Trial Strategy
PremiumCompany Announcements
Day One Biopharmaceuticals Updates FIREFLY-2 Trial Strategy
1M ago
BrightSpring Health announces Onco360 selected as partner for OJEMDA
PremiumThe FlyBrightSpring Health announces Onco360 selected as partner for OJEMDA
2M ago
Day One price target lowered to $40 from $50 at H.C. Wainwright
PremiumThe Fly
Day One price target lowered to $40 from $50 at H.C. Wainwright
3M ago
Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
PremiumThe Fly
Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
3M ago
Day One comments from call weighing on sentiment, says BofA
PremiumThe FlyDay One comments from call weighing on sentiment, says BofA
3M ago
Xoma earns $9M milestone as FDA grants approval of Day One’s NDA for OJEMDA
PremiumThe Fly
Xoma earns $9M milestone as FDA grants approval of Day One’s NDA for OJEMDA
3M ago
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
PremiumCompany Announcements
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100